Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind, placebo-controlled study of single ascending doses of PTG-300 in normal healthy male subjects

Trial Profile

A randomized, double-blind, placebo-controlled study of single ascending doses of PTG-300 in normal healthy male subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 18 Jun 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PTG 300 (Primary)
  • Indications Beta-thalassaemia
  • Focus Adverse reactions; First in man; Proof of concept
  • Sponsors Protagonist Therapeutics
  • Most Recent Events

    • 18 Jun 2018 According to a Protagonist Therapeutics media release, data from this study were presented at the 23rd Congress of the European Hematology Association (EHA)
    • 14 Dec 2017 Status changed from recruiting to completed, according to a Protagonist Therapeutics media release.
    • 14 Dec 2017 Results, which included the successful completion of the study extension of two dose cohorts, published in a Protagonist Therapeutics Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top